Paper · 41930337
Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions.
Cheng B and 6 others. MedComm (2020), 2026. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions. Papers, record 41930337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41930337
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References143
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40,698,965 | Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations. | Future Oncol | 2025 | https://conductscience.org/library/papers/40698965 | PubMed |
| 2 | 31,689,155 | Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31689155 | PubMed |
| 3 | 37,754,497 | Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective. | Curr Oncol | 2023 | https://conductscience.org/library/papers/37754497 | PubMed |
| 4 | 40,473,459 | Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI. | J Nucl Med | 2025 | https://conductscience.org/library/papers/40473459 | PubMed |
| 5 | 31,825,192 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31825192 | PubMed |
| 6 | 40,989,107 | Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors. | Antib Ther | 2025 | https://conductscience.org/library/papers/40989107 | PubMed |
| 7 | 40,843,358 | The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy. | Cancer Drug Resist | 2025 | https://conductscience.org/library/papers/40843358 | PubMed |
| 8 | 40,800,161 | Datopotamab deruxtecan induces hallmarks of immunogenic cell death. | Cell Stress | 2025 | https://conductscience.org/library/papers/40800161 | PubMed |
| 9 | 40,175,391 | Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). | Nat Commun | 2025 | https://conductscience.org/library/papers/40175391 | PubMed |
| 10 | 37,296,177 | Optimizing the safety of antibody-drug conjugates for patients with solid tumours. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/37296177 | PubMed |
1 to 10 of 143
See all 143 referencesCited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,980,888 | Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42980888 | PubMed |
| 42,978,398 | Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate (ADC) Development Lifecycle. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42978398 | PubMed |
| 42,793,224 | Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42793224 | PubMed |
| 42,449,646 | Advances and Future Directions in Antibody-Drug Conjugates: From Paradigm Shifts to Data-Driven Design. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449646 | PubMed |
| 42,352,921 | Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression: A Mechanistic, Translational, and Clinical Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42352921 | PubMed |
| 42,341,371 | Comprehensive analysis of antibody-drug conjugate (ADC) targets in adenoid cystic carcinoma: examining antigen expression in relation to clinicopathological features, prognosis, and initial therapeutic outcomes. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42341371 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41930337
GET https://conductscience.org/api/papers/v1/41930337/references?page=2